In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, manager of oncology clinical pharmacy services at Allegheny Health Network in Pittsburgh, discusses ASCO’s updated guideline for follow-up and surveillance after primary treatment for early-stage breast cancer.
In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.
Angie Maynard, PharmD, MS, BCOP, discusses RCC immunotherapy guidelines, treatment selection, toxicity management, and pharmacists’ clinical role.
Andrew Li, PharmD, BCOP, discusses key targeted therapy updates in the 2026 ASCO living guideline for stage IV non–small cell lung cancer and how pharmacists can help manage treatment-related toxicities and access barriers.
Vince Sung, PharmD, MBA, BCOP, BCPS, discusses the clinical implications of the updated prostate cancer guidelines.
Christine Barrett, PharmD, BCOP discusses key updates to the Systemic Treatment of Thyroid Cancer: ASCO Guideline.
Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.
ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.
